Search research articles
Contact Us
Filters
Showing results (101-110 of 301) with videos related to
Page
of 31
Sort By:
European Journal of Haematology
|
March 24, 2009
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A Stadtmauer, Donna M Weber, Ruben Niesvizky, et al.
Cancer Research
|
February 4, 2012
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma
Jill Corre, Elodie Labat, Nicolas Espagnolle, et al.
Clinical Hematology International
|
February 13, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, et al.
Clinical Hematology International
|
October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?
Anna Suska, David H Vesole, Jorge J Castillo, et al.
American Journal of Hematology
|
August 12, 2021
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold, Sara Bringhen, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
Asher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology
|
April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Cancer
|
August 8, 2013
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, et al.
British Journal of Haematology
|
May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Hang Quach, Ajay Nooka, Olga Samoylova, et al.
Seminars in Hematology
|
June 5, 2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials
François Guilhot, Martine Gardembas, Philippe Rousselot, et al.
Page
of 31
Search research articles
Search
Showing results (101-110 of 301) with videos related to
Sort By:
Page
of 31
European Journal of Haematology
|
March 24, 2009
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A Stadtmauer, Donna M Weber, Ruben Niesvizky, et al.
Cancer Research
|
February 4, 2012
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma
Jill Corre, Elodie Labat, Nicolas Espagnolle, et al.
Clinical Hematology International
|
February 13, 2023
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, et al.
Clinical Hematology International
|
October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?
Anna Suska, David H Vesole, Jorge J Castillo, et al.
American Journal of Hematology
|
August 12, 2021
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold, Sara Bringhen, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
Asher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
British Journal of Haematology
|
April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
Paul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Cancer
|
August 8, 2013
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, et al.
British Journal of Haematology
|
May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Hang Quach, Ajay Nooka, Olga Samoylova, et al.
Seminars in Hematology
|
June 5, 2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials
François Guilhot, Martine Gardembas, Philippe Rousselot, et al.
Page
of 31